...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

"The question I have is now that we have the Moderna and Pfizer vaccines, what impact does this really have?  Plus there is also the AstraZeneca vaccine.  I'm just trying to figure out where this fits in now from a COVID perspective."

My personal opinion, based on seeing the publicly available efficacy data and the safety profiles for the Moderna and BioNTech/Pfizer mRNA based vaccines, is that the world is going to have sufficient safe and effective vaccine available (from Moderna, BioNTech/Pfizer, and other non-mRNA based vaccines on the way) to make COVID-19 BET inhibitor therapies more or less pointless. By the time an apabetalone COVID-19 trial is complete, a large percentage of the world will likely have been vaccinated.

There may be space for apabetalone treatment of people who are infected but did not get vaccinated, or those who get infected despite getting vaccinated (due to vaccine waning or lack of protection). But if all goes as planned the widespread vaccination and hopefully herd immunity will make a second-line therapy like apabetalone unnecessary.

BDAZ

Share
New Message
Please login to post a reply